Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-06-2009

A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis

Authors: Torsten Stein, Nathan Salomonis, Dimitry S. A. Nuyten, Marc J. van de Vijver, Barry A. Gusterson

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 2/2009

Abstract

Mouse mammary gland involution resembles a wound healing response with suppressed inflammation. Wound healing and inflammation are also associated with tumour development, and a ‘wound-healing’ gene expression signature can predict metastasis formation and survival. Recent studies have shown that an involuting mammary gland stroma can promote metastasis. It could therefore be hypothesised that gene expression signatures from an involuting mouse mammary gland may provide new insights into the physiological pathways that promote breast cancer progression. Indeed, using the HOPACH clustering method, the human orthologues of genes that were differentially regulated at day 3 of mammary gland involution and showed prolonged expression throughout the first 4 days of involution distinguished breast cancers in the NKI 295 breast cancer dataset with low and high metastatic activity. Most strikingly, genes associated with copper ion homeostasis and with HIF-1 promoter binding sites were the most over-represented, linking this signature to hypoxia. Further, six out of the ten mRNAs with strongest up-regulation in cancers with poor survival code for secreted factors, identifying potential candidates that may be involved in stromal/matrix-enhanced metastasis formation/breast cancer development. This method therefore identified biological processes that occur during mammary gland involution, which may be critical in promoting breast cancer metastasis that could form a basis for future investigation, and supports a role for copper in breast cancer development.

Available only for authorised users

Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004;6:R92–109. doi:10.1186/bcr754.PubMedCrossRef

Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res. 2004;6:R75–91. doi:10.1186/bcr753.PubMedCrossRef

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. doi:10.1038/nature01322.PubMedCrossRef

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.PubMed

McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol. 2006;168:608–20. doi:10.2353/ajpath.2006.050677.PubMedCrossRef

Schedin P, O'Brien J, Rudolph M, Stein T, Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia. 2007;12:71–82. doi:10.1007/s10911-007-9039-3.PubMedCrossRef

Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005;102:3738–43. doi:10.1073/pnas.0409462102.PubMedCrossRef

Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2:E7. doi:10.1371/journal.pbio.0020007.PubMedCrossRef

Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3:e47. doi:10.1371/journal.pmed.0030047.PubMedCrossRef

10.

Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005;65:4059–66. doi:10.1158/0008-5472.CAN-04-3953.PubMedCrossRef

11.

Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;24:1665–71. doi:10.1200/JCO.2005.03.9115.PubMedCrossRef

12.

Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006;24:1656–64. doi:10.1200/JCO.2005.03.2755.PubMedCrossRef

13.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. doi:10.1038/35021093.PubMedCrossRef

14.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74. doi:10.1073/pnas.191367098.PubMedCrossRef

15.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23. doi:10.1073/pnas.0932692100.PubMedCrossRef

16.

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–8. doi:10.1073/pnas.1732912100.PubMedCrossRef

17.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–72.PubMedCrossRef

18.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6. doi:10.1038/415530a.PubMedCrossRef

19.

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671–9.PubMed

20.

West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005;3:e187. doi:10.1371/journal.pbio.0030187.PubMedCrossRef

21.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. doi:10.1056/NEJMoa021967.PubMedCrossRef

22.

Salomonis N, Cotte N, Zambon AC, Pollard KS, Vranizan K, Doniger SW, et al. Identifying genetic networks underlying myometrial transition to labor. Genome Biol. 2005;6:R12. doi:10.1186/gb-2005-6-2-r12.PubMedCrossRef

23.

Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003;4:R7. doi:10.1186/gb-2003-4-1-r7.PubMedCrossRef

24.

Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 2002;31:19–20. doi:10.1038/ng0502-19.PubMedCrossRef

25.

Mi H, Guo N, Kejariwal A, Thomas PD. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007;35:D247–52. doi:10.1093/nar/gkl869.PubMedCrossRef

26.

Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D, et al. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol. 2005;115:93–101. doi:10.1016/j.clim.2004.12.002.PubMedCrossRef

27.

Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 2003;162:1521–8.PubMed

28.

Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA. 2006;103:18721–6. doi:10.1073/pnas.0609025103.PubMedCrossRef

29.

Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell. 2004;6:471–83. doi:10.1016/j.ccr.2004.09.029.PubMedCrossRef

30.

van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716–28. doi:10.1161/01.ATV.0000209518.58252.17.PubMedCrossRef

31.

NicAmhlaoibh R, Shtivelman E. Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. Oncogene. 2001;20:270–5. doi:10.1038/sj.onc.1204075.PubMedCrossRef

32.

Hayrabedyan S, Kyurkchiev S, Kehayov I. FGF-1 and S100A13 possibly contribute to angiogenesis in endometriosis. J Reprod Immunol. 2005;67:87–101. doi:10.1016/j.jri.2005.07.001.PubMedCrossRef

33.

Iizuka M, Abe M, Shiiba K, Sasaki I, Sato Y. Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J Vasc Res. 2004;41:334–44. doi:10.1159/000079832.PubMedCrossRef

34.

Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. J Mammary Gland Biol Neoplasia. 2007;12:25–35. doi:10.1007/s10911-007-9035-7.PubMedCrossRef

35.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45. doi:10.1016/S0140-6736(00)04046-0.PubMedCrossRef

36.

Blanchard A, Shiu R, Booth S, Sorensen G, DeCorby N, Nistor A, et al. Gene expression profiling of early involuting mammary gland reveals novel genes potentially relevant to human breast cancer. Front Biosci. 2007;12:2221–32. doi:10.2741/2225.PubMedCrossRef

37.

Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8:R62. doi:10.1186/bcr1614.PubMedCrossRef

38.

Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–60. doi:10.1038/nrc1361.PubMedCrossRef

39.

Orlowski RZ, Dees EC. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003;5:1–7. doi:10.1186/bcr460.PubMedCrossRef

40.

Daniel KG, Chen D, Yan B, Dou QP. Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer. Front Biosci. 2007;12:135–44. doi:10.2741/2054.PubMedCrossRef

41.

Daniel KG, Kuhn DJ, Kazi A, Dou QP. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr Cancer Drug Targets. 2005;5:529–41. doi:10.2174/156800905774574075.PubMedCrossRef

42.

Monks J, Geske FJ, Lehman L, Fadok VA. Do inflammatory cells participate in mammary gland involution? J Mammary Gland Biol Neoplasia. 2002;7:163–76. doi:10.1023/A:1020351919634.PubMedCrossRef

43.

Monks J, Smith-Steinhart C, Kruk ER, Fadok VA, Henson PM. Epithelial cells remove apoptotic epithelial cells during post-lactation involution of the mouse mammary gland. Biol Reprod. 2008;78:586–94. doi:10.1095/biolreprod.107.065045.PubMedCrossRef

44.

Kelleher SL, Lonnerdal B. Mammary gland copper transport is stimulated by prolactin through alterations in Ctr1 and Atp7A localization. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1181–91. doi:10.1152/ajpregu.00206.2005.PubMed

45.

Keen CL, Lonnerdal B, Clegg M, Hurley LS. Developmental changes in composition of rat milk: trace elements, minerals, protein, carbohydrate and fat. J Nutr. 1981;111:226–36.PubMed

46.

Cerveza PJ, Mehrbod F, Cotton SJ, Lomeli N, Linder MC, Fonda EG, et al. Milk ceruloplasmin and its expression by mammary gland and liver in pigs. Arch Biochem Biophys. 2000;373:451–61. doi:10.1006/abbi.1999.1572.PubMedCrossRef

47.

Donley SA, Ilagan BJ, Rim H, Linder MC. Copper transport to mammary gland and milk during lactation in rats. Am J Physiol Endocrinol Metab. 2002;283:E667–75.PubMed

48.

Linder MC, Wooten L, Cerveza P, Cotton S, Shulze R, Lomeli N. Copper transport. Am J Clin Nutr. 1998;67:965S–71S.PubMed

49.

Jaeger JL, Shimizu N, Gitlin JD. Tissue-specific ceruloplasmin gene expression in the mammary gland. Biochem J. 1991;280(Pt 3):671–7.PubMed

50.

Michalczyk A, Bastow E, Greenough M, Camakaris J, Freestone D, Taylor P, et al. ATP7B expression in human breast epithelial cells is mediated by lactational hormones. J Histochem Cytochem. 2008;56:389–99. doi:10.1369/jhc.7A7300.2008.PubMedCrossRef

51.

Llanos RM, Michalczyk AA, Freestone DJ, Currie S, Linder MC, Ackland ML, et al. Copper transport during lactation in transgenic mice expressing the human ATP7A protein. Biochem Biophys Res Commun. 2008;372:613–7. doi:10.1016/j.bbrc.2008.05.123.PubMedCrossRef

52.

Hamza I, Prohaska J, Gitlin JD. Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes ATPase. Proc Natl Acad Sci USA. 2003;100:1215–20. doi:10.1073/pnas.0336230100.PubMedCrossRef

53.

Hamza I, Faisst A, Prohaska J, Chen J, Gruss P, Gitlin JD. The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proc Natl Acad Sci USA. 2001;98:6848–52. doi:10.1073/pnas.111058498.PubMedCrossRef

54.

Linder MC. Copper and genomic stability in mammals. Mutat Res. 2001;475:141–52. doi:10.1016/S0027-5107(01)00076-8.PubMed

55.

Goldstein IM, Kaplan HB, Edelson HS, Weissmann G. A new function for ceruloplasmin as an acute-phase reactant in inflammation: a scavenger of superoxide anion radicals. Trans Assoc Am Physicians. 1979;92:360–9.PubMed

56.

Goldstein IM, Kaplan HB, Edelson HS, Weissmann G. Ceruloplasmin: an acute phase reactant that scavenges oxygen-derived free radicals. Ann N Y Acad Sci. 1982;389:368–79. doi:10.1111/j.1749-6632.1982.tb22150.x.PubMedCrossRef

57.

Geraki K, Farquharson MJ, Bradley DA. Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study. Phys Med Biol. 2002;47:2327–39. doi:10.1088/0031-9155/47/13/310.PubMedCrossRef

58.

Geraki K, Farquharson MJ, Bradley DA. X-ray fluorescence and energy dispersive x-ray diffraction for the quantification of elemental concentrations in breast tissue. Phys Med Biol. 2004;49:99–110. doi:10.1088/0031-9155/49/1/007.PubMedCrossRef

59.

Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35:32–46. doi:10.1016/j.ctrv.2008.07.004.PubMedCrossRef

60.

Lowndes SA, Harris AL. The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia. 2005;10:299–310. doi:10.1007/s10911-006-9003-7.PubMedCrossRef

61.

Gupta SK, Shukla VK, Vaidya MP, Roy SK, Gupta S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J Surg Oncol. 1991;46:178–81. doi:10.1002/jso.2930460311.PubMedCrossRef

62.

Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 2006;234:34–9. doi:10.1016/j.canlet.2005.07.046.PubMedCrossRef

63.

Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002;62:4854–9.PubMed

64.

Brewer GJ. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets. 2005;5:195–202. doi:10.2174/1568009053765807.PubMedCrossRef

65.

Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001;61:3869–76.PubMed

66.

Stassar MJ, Devitt G, Brosius M, Rinnab L, Prang J, Schradin T, et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer. 2001;85:1372–82. doi:10.1054/bjoc.2001.2074.PubMedCrossRef

67.

Song B. Immunohistochemical demonstration of epidermal growth factor receptor and ceruloplasmin in thyroid diseases. Acta Pathol Jpn. 1991;41:336–43.PubMed

68.

Tuccari G, Barresi G. Immunohistochemical demonstration of ceruloplasmin in follicular adenomas and thyroid carcinomas. Histopathology. 1987;11:723–31. doi:10.1111/j.1365-2559.1987.tb02686.x.PubMedCrossRef

69.

Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96. doi:10.1186/1471-2164-7-96

70.

Schapira DV, Schapira M. Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer. Breast Cancer Res Treat. 1983;3:221–4. doi:10.1007/BF01803564.PubMedCrossRef

71.

Martin F, Linden T, Katschinski DM, Oehme F, Flamme I, Mukhopadhyay CK, et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood. 2005;105:4613–9. doi:10.1182/blood-2004-10-3980.PubMedCrossRef

72.

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–24. doi:10.1038/nature03799.PubMedCrossRef

73.

Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007;7:139–47. doi:10.1038/nrc2067.PubMedCrossRef

74.

Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R, Okuda H, et al. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer. 2001;94:768–73. doi:10.1002/ijc.1537.PubMedCrossRef

75.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, et al. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression. Oncol Rep. 2003;10:1369–73.PubMed

76.

Yoshiji H, Yoshii J, Kuriyama S, Ikenaka Y, Noguchi R, Yanase K, et al. Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice. Oncol Rep. 2005;14:213–8.PubMed

77.

Das D, Tapryal N, Goswami SK, Fox PL, Mukhopadhyay CK. Regulation of ceruloplasmin in human hepatic cells by redox active copper: identification of a novel AP-1 site in the ceruloplasmin gene. Biochem J. 2007;402:135–41. doi:10.1042/BJ20060963.PubMedCrossRef

78.

Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 2007;67:563–72. doi:10.1158/0008-5472.CAN-06-2701.PubMedCrossRef

79.

Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005;116:734–9. doi:10.1002/ijc.20984.PubMedCrossRef

80.

Zheng X, Ruas JL, Cao R, Salomons FA, Cao Y, Poellinger L, et al. Cell-type-specific regulation of degradation of hypoxia-inducible factor 1 alpha: role of subcellular compartmentalization. Mol Cell Biol. 2006;26:4628–41. doi:10.1128/MCB.02236-05.PubMedCrossRef

81.

Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res. 2005;25:3003–9.PubMed

82.

Seagroves TN, Hadsell D, McManaman J, Palmer C, Liao D, McNulty W, et al. HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development. 2003;130:1713–24. doi:10.1242/dev.00403.PubMedCrossRef

83.

Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J. 2000;346(Pt 3):603–10. doi:10.1042/0264-6021:3460603.PubMedCrossRef

84.

Anderson SM, Rudolph MC, McManaman JL, Neville MC. Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! Breast Cancer Res. 2007;9:204. doi:10.1186/bcr1653

85.

Rudolph MC, McManaman JL, Phang T, Russell T, Kominsky DJ, Serkova NJ, et al. Metabolic regulation in the lactating mammary gland: a lipid synthesizing machine. Physiol Genomics. 2007;28:323–36. doi:10.1152/physiolgenomics.00020.2006.PubMed

86.

Rudolph MC, Neville MC, Anderson SM. Lipid synthesis in lactation: diet and the fatty acid switch. J Mammary Gland Biol Neoplasia. 2007;12:269–81. doi:10.1007/s10911-007-9061-5.PubMedCrossRef

87.

Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77. doi:10.1038/nrc2222.PubMedCrossRef

88.

Ning Y, Hoang B, Schuller AG, Cominski TP, Hsu MS, Wood TL, et al. Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene. Endocrinology. 2007;148:2138–47. doi:10.1210/en.2006-0041.PubMedCrossRef

89.

Tonner E, Barber MC, Allan GJ, Beattie J, Webster J, Whitelaw CB, et al. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development. 2002;129:4547–57.PubMed

90.

Flint DJ, Boutinaud M, Tonner E, Wilde CJ, Hurley W, Accorsi PA, et al. Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland. Domest Anim Endocrinol. 2005;29:274–82. doi:10.1016/j.domaniend.2005.02.021.PubMedCrossRef

91.

Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology. 2003;144:2807–15. doi:10.1210/en.2002-221086.PubMedCrossRef

92.

Akkiprik M, Feng Y, Wang H, Chen K, Hu L, Sahin A, et al. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res. 2008;10:212. doi:10.1186/bcr2116.PubMedCrossRef

93.

Li X, Cao X, Li X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci. 2007;98:1592–6. doi:10.1111/j.1349-7006.2007.00565.x.PubMedCrossRef

94.

Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, et al. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol. 2007;37:575–82. doi:10.1093/jjco/hym066.PubMedCrossRef

95.

Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008;14:261–7. doi:10.1111/j.1524-4741.2008.00572.x.PubMedCrossRef

96.

Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y, et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 2004;100:1110–22. doi:10.1002/cncr.20095.PubMedCrossRef

97.

Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005;21:695–718. doi:10.1146/annurev.cellbio.21.122303.120306.PubMedCrossRef

98.

Wang W, Wyckoff JB, Wang Y, Bottinger EP, Segall JE, Condeelis JS. Gene expression analysis on small numbers of invasive cells collected by chemotaxis from primary mammary tumors of the mouse. BMC Biotechnol. 2003;3:13. doi:10.1186/1472-6750-3-13.PubMedCrossRef

99.

Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186. doi:10.1186/1471-2407-6-186.PubMedCrossRef

100.

Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M, et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol. 2005;168:441–52. doi:10.1083/jcb.200407076.PubMedCrossRef

101.

Agarwal R, D'Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005;65:7378–85. doi:10.1158/0008-5472.CAN-05-1036.PubMedCrossRef

102.

Huang YH, Bao Y, Peng W, Goldberg M, Love K, Bumcrot DA, et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci USA. 2009;106:3426–30. doi:10.1073/pnas.0813348106.PubMedCrossRef

103.

Carraway KL 3rd, Sweeney C. Co-opted integrin signaling in ErbB2-induced mammary tumor progression. Cancer Cell. 2006;10:93–5. doi:10.1016/j.ccr.2006.07.015.PubMedCrossRef

104.

Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol. 1998;140:1383–93. doi:10.1083/jcb.140.6.1383.PubMedCrossRef

105.

Otey CA, Pavalko FM, Burridge K. An interaction between alpha-actinin and the beta 1 integrin subunit in vitro. J Cell Biol. 1990;111:721–9. doi:10.1083/jcb.111.2.721.PubMedCrossRef

106.

Burridge K, Nuckolls G, Otey C, Pavalko F, Simon K, Turner C. Actin-membrane interaction in focal adhesions. Cell Differ Dev. 1990;32:337–42. doi:10.1016/0922-3371(90)90048-2.PubMedCrossRef

107.

Dudoit S, Gentleman RC, Quackenbush J. Open source software for the analysis of microarray data. Biotechniques. 2003;(Suppl):45–51.

108.

Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Stat Assoc. 2004;99:909–17. doi:10.1198/016214504000000683.CrossRef

109.

Nuyten DS, Hastie T, Chi JT, Chang HY, van de Vijver MJ. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. Eur J Cancer. 2008;44:2319–29. doi:10.1016/j.ejca.2008.07.015.PubMedCrossRef

110.

Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2006;34:D173–80. doi:10.1093/nar/gkj158.PubMedCrossRef

Title: A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis
Authors: Torsten Stein
Nathan Salomonis
Dimitry S. A. Nuyten
Marc J. van de Vijver
Barry A. Gusterson
Publication date: 01-06-2009
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 2/2009
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-009-9120-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer

Mammary Involution and Breast Cancer Risk: Transgenic Models and Clinical Studies

Transforming Growth Factor-βs and Mammary Gland Involution; Functional Roles and Implications for Cancer Progression

Macrophages in Breast Cancer: Do Involution Macrophages Account for the Poor Prognosis of Pregnancy-Associated Breast Cancer?

A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis

Pregnancy and Breast Cancer: when They Collide

Keynote webinar | Spotlight on antibody–drug conjugates in cancer